As of March 31, 2026, Moderna Inc. (NASDAQ: MRNA) finds itself at a defining historical junction. After years of being defined by a single, world-altering product—its COVID-19 vaccine—the Cambridge-based biotechnology pioneer is mid-pivot into what CEO Stéphane Bancel describes as "Moderna 2.0." The company that once boasted a market capitalization exceeding $150 billion during the [...]
In a landmark moment for respiratory medicine and biotechnology, United Therapeutics (NASDAQ:UTHR) announced late Monday, March 30, 2026, that its pivotal TETON-1 Phase 3 study for nebulized Tyvaso (treprostinil) in patients with idiopathic pulmonary fibrosis (IPF) was a resounding success. The news sent shockwaves through the financial markets, propelling
Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements...
The biotechnology sector witnessed a seismic shift on March 26, 2026, as shares of Corcept Therapeutics (NASDAQ: CORT) surged 19.66% in heavy trading. The rally, which added nearly $1 billion to the company’s market capitalization, was triggered by a "perfect storm" of positive regulatory developments and breakthrough clinical
Check out the companies making headlines yesterday: Robinhood (NASDAQ:HOOD): Financial services company Robinhood (NASDAQ:HOOD) rose by 4.8% on Wednesday aft...
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the branded pharmaceuticals industry, including Eli Lilly (NYSE:L...
What Happened? Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) jumped 2.6% in the afternoon session after its positive momentum continued...
As of March 25, 2026, Merck & Co., Inc. (NYSE: MRK) stands at a pivotal crossroads in its 135-year history. Known globally as a titan of oncology and vaccines, the Rahway, New Jersey-based pharmaceutical giant is currently navigating one of the most significant strategic transformations in the healthcare sector. At the center of this evolution [...]
Shares of pharmaceutical giant Bristol-Myers Squibb (NYSE:BMY) climbed 3.3% in early trading on Monday, March 23, 2026, after the company issued a surprisingly robust financial outlook for the fiscal year. Investors rallied behind the company’s projection of significant revenue growth and resilient earnings, signaling a renewed confidence
In a landmark decision for the dermatology sector, the U.S. Food and Drug Administration (FDA) has officially approved ICOTYDE™ (icotrokinra), a first-of-its-kind oral peptide for the treatment of moderate-to-severe plaque psoriasis. Developed through a high-stakes collaboration between Protagonist Therapeutics (Nasdaq: PTGX) and Johnson & Johnson (NYSE: JNJ), the approval marks
The pharmaceutical giant AbbVie (NYSE: ABBV) experienced a sharp decline on Wednesday, March 18, 2026, as its stock price tumbled to its lowest level since mid-2025. Shares of the Illinois-based company fell nearly 4% during the session, trading in the range of $211 to $219, a stark contrast to the
As the first quarter of 2026 draws to a close, the S&P 500 is witnessing one of the most dramatic sector performance splits in recent financial history. According to consensus estimates as of March 17, 2026, the Finance sector is projected to report a staggering 19% year-over-year earnings growth,
Amidst a backdrop of mounting geopolitical tensions and sharp swings in the broader indices, pharmaceutical giant Merck & Co. (NYSE: MRK) officially trades ex-dividend today, March 16, 2026. Investors who held the stock prior to today’s session are now locked in to receive a quarterly payout of $0.85 per
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant ch...
In a watershed moment for the biotechnology sector, BioNTech SE (NASDAQ: BNTX) has reported its full-year 2025 financial results, signaling the definitive end of the COVID-19 vaccine gold rush and the beginning of a high-stakes pivot toward oncology. The German biotech pioneer recorded a net loss of €1.1 billion
